SLC35A2 and Hyperbilirubinemia: Atazanavir-induced hyperbilirubinemia is indirect hyperbilirubinemia that is created by inhibition of the UDP-glucuronyltransferase (UGT) enzyme that conjugates bilirubin, which is associated with genetic characteristics [23].